EJSW may treat ITP by inhibiting the expression of TNF-α, IL-1β, and other inflammatory factors, and by protecting vascular integrity through VEGF signalling, AGE-RAGE signalling, and complement and coagulation cascade signalling pathways. The gene discussed is VEGFA; the disease is autoimmune thrombocytopenic purpura.